723 related articles for article (PubMed ID: 6176669)
21. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms.
Funk J; Schmitz G; Failing K; Burkhardt E
Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143
[TBL] [Abstract][Full Text] [Related]
22. Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.
Ames IH; Gates CE; Garcia AM; John PA; Hennig AK; Tomar RH
Cancer Immunol Immunother; 1987; 25(3):161-8. PubMed ID: 3499983
[TBL] [Abstract][Full Text] [Related]
23. Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants.
Hersh EM; Scuderi P; Grimes WJ; Chong A; Brailey JL; Gschwind CR; Salmon SE
Cancer Immunol Immunother; 1989; 30(1):65-70. PubMed ID: 2480843
[TBL] [Abstract][Full Text] [Related]
24. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
Rodolfo M; Salvi C; Parmiani G
Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
[TBL] [Abstract][Full Text] [Related]
26. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
27. Lysis of endothelial cells by autologous lymphokine-activated killer cells.
Kitayama J; Tsuno N; Yasuhara H; Nagawa H; Kimura W; Kuroda A; Shibata Y; Juji T; Muto T
Cancer Immunol Immunother; 1994 May; 38(5):317-22. PubMed ID: 8162614
[TBL] [Abstract][Full Text] [Related]
28. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).
Pawelec G; Schneider E; Ehninger G; Rehbein A; Schmidt H
Cancer Immunol Immunother; 1989; 29(1):63-6. PubMed ID: 2785001
[TBL] [Abstract][Full Text] [Related]
29. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.
Melder RJ; Rosenfeld CS; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1989; 29(1):67-73. PubMed ID: 2785002
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.
Grimm EA; Crump WL; Durett A; Hester JP; Lagoo-Deenadalayan S; Owen-Schaub LB
Cancer Immunol Immunother; 1988; 27(1):53-8. PubMed ID: 3260821
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating lymphocytes from nonrenal urological malignancies.
Haas GP; Solomon D; Rosenberg SA
Cancer Immunol Immunother; 1990; 30(6):342-50. PubMed ID: 2105845
[TBL] [Abstract][Full Text] [Related]
32. High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.
Roussel E; Gingras MC; Grimm EA; Roth JA
Cancer Immunol Immunother; 1995 Jul; 41(1):1-9. PubMed ID: 7641214
[TBL] [Abstract][Full Text] [Related]
33. Role of proliferation in LAK cell development.
Ramsdell FJ; Shau H; Golub SH
Cancer Immunol Immunother; 1988; 26(2):139-44. PubMed ID: 3129192
[TBL] [Abstract][Full Text] [Related]
34. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
Radrizzani M; Gambacorti-Passerini C; Parmiani G; Fossati G
Cancer Immunol Immunother; 1989; 28(1):67-73. PubMed ID: 2462469
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Mulé JJ; Schwarz SL; Roberts AB; Sporn MB; Rosenberg SA
Cancer Immunol Immunother; 1988; 26(2):95-100. PubMed ID: 2452015
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients.
Yamaguchi T; Suzuki Y; Katakura R; Ebina T; Yokoyama J; Fujimiya Y
Cancer Immunol Immunother; 1998 Oct; 47(2):97-103. PubMed ID: 9769118
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of in vitro LAK generation by OK-432.
Yagita M; Grimm EA
Cancer Immunol Immunother; 1986; 23(3):207-13. PubMed ID: 3491681
[TBL] [Abstract][Full Text] [Related]
38. Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.
Schwarz RE; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1989; 30(5):312-6. PubMed ID: 2624925
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
40. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK.
Kariya Y; Okamoto N; Fujimoto T; Inoue N; Kihara T; Sugie K; Yagita M; Kanzaki H; Mori T; Uchida A
Jpn J Cancer Res; 1991 Sep; 82(9):1044-50. PubMed ID: 1938599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
